Summary: Cellular immunotherapy using allogeneic natural killer (NK) cells may overcome chemotherapy-refractory acute myeloid leukemia. Our goal was to document NK cell homing/persistence in the bone marrow following adoptive immunotherapy. Our cohort included 109 patients who received NK cell therapy for refractory acute myeloid leukemia following lymphodepleting conditioning +/− denileukin diftitox, +/− low-dose total body irradiation. We evaluated the NK cell density in bone marrow core biopsies performed an average of 14 days after NK cell transfer using a CD56 immunohistochemical stain. The NK cell density in core biopsies showed only moderate correlation with NK cell percentage in bone marrow aspirates evaluated by flow cytometry (r s = 0.48) suggesting that distribution of CD56 + cells in the bone marrow niche offers unique insight into NK cell homing. Better leukemia control was associated with increased NK cell density, such that patients with <5% blasts had a higher NK cell density (P = 0.01). As well, NK cell density above the median of reference group was significantly associated with morphologic remission of leukemia (P = 0.01). Moreover, the NK cell density varied significantly between conditioning protocols. Our findings suggest that the use of low-dose irradiation or CD25-targeting immunocytokine (denileukin diftitox, IL2DT) as part of conditioning results in increased NK cell homing/ persistence in the bone marrow. These novel results will help guide future immunotherapy with NK cells. The use of NK cells as cellular immunotherapy for patients with refractory acute myeloid leukemia (AML) is, and has been, an area of active research. The University of Minnesota has conducted clinical trials with adoptive immunotherapy using allogeneic NK cells for over a decade. 5 In this approach, allogeneic NK cells are isolated from the donor peripheral blood mononuclear cells, activated overnight in vitro and infused following preparatory lymphodepleting regimen (fludarabine/cyclophosphamide). Following NK cell transfer, stimulatory cytokines such as interleukin 2 (IL-2) or interleukin 15 (IL-15) are administered to the recipient to promote NK cell expansion. Such treatment has induced leukemia remission in a subset of patients with chemotherapy-refractory AML. 6 In vivo persistence of donor NK cells in the blood has been observed in some recipients and is associated with increased likelihood of leukemia clearance. 5, 6 Less is known about homing and persistence of infused allogeneic NK cells in the bone marrow niche, the primary site of disease burden in leukemia. Bone marrow is the primary site of NK cell development and is the site of expansion and proliferation of NK cells in the setting of viral infection. 7, 8 The mechanisms controlling trafficking of NK cells to and from the bone marrow are relatively less well studied and include the CXCR4-CXCL12 axis as well as CXCR3, CCR1 and CX3CR1 and S1P 5 receptors. 9 Recent studies in animal model showed that NK cells are actively patrolling the bone marrow and when stimulated they can actively enter the bone marrow parenchyma, where they proliferate and expand. 10 Relatively less is known about the number and distribution of NK cells in human bone marrow.
(J Immunother 2019;42:65-72) N atural killer (NK) cells are a part of the innate immune system able to secrete cytokines and kill virally infected or malignant cells without previous sensitization. 1,2 Unlike T lymphocytes or B lymphocytes, NK cells do not undergo rearrangement of unique antigen-specific receptors; rather variable sets of activating and inhibitory receptors control their activity. Nevertheless, a subset of NK cells can be longlived and show adaptive properties with amplification of recall responses to chemical haptens and viruses. 3, 4 The use of NK cells as cellular immunotherapy for patients with refractory acute myeloid leukemia (AML) is, and has been, an area of active research. The University of Minnesota has conducted clinical trials with adoptive immunotherapy using allogeneic NK cells for over a decade. 5 In this approach, allogeneic NK cells are isolated from the donor peripheral blood mononuclear cells, activated overnight in vitro and infused following preparatory lymphodepleting regimen (fludarabine/cyclophosphamide). Following NK cell transfer, stimulatory cytokines such as interleukin 2 (IL-2) or interleukin 15 (IL-15) are administered to the recipient to promote NK cell expansion. Such treatment has induced leukemia remission in a subset of patients with chemotherapy-refractory AML. 6 In vivo persistence of donor NK cells in the blood has been observed in some recipients and is associated with increased likelihood of leukemia clearance. 5, 6 Less is known about homing and persistence of infused allogeneic NK cells in the bone marrow niche, the primary site of disease burden in leukemia. Bone marrow is the primary site of NK cell development and is the site of expansion and proliferation of NK cells in the setting of viral infection. 7, 8 The mechanisms controlling trafficking of NK cells to and from the bone marrow are relatively less well studied and include the CXCR4-CXCL12 axis as well as CXCR3, CCR1 and CX3CR1 and S1P 5 receptors. 9 Recent studies in animal model showed that NK cells are actively patrolling the bone marrow and when stimulated they can actively enter the bone marrow parenchyma, where they proliferate and expand. 10 Relatively less is known about the number and distribution of NK cells in human bone marrow.
Our study goal was to document NK cell homing/ persistence in the bone marrow following adoptive immunotherapy. To this aim, we studied the number and distribution of NK cells in bone marrow biopsies performed routinely 2-3 weeks after adoptive transfer in patients with chemotherapy-refractory AML. The results show variability in the density of NK cells in the bone marrow, correlating with disease clearance. Moreover, we observed significant differences in the density of NK cells between clinical immunotherapy protocols. Our analysis suggests that the use of total body irradiation (TBI) or CD25-targeting immunocytokine (denileukin diftitox, IL2DT) as part of conditioning result in increased density of CD56 + cells in the bone marrow. These findings offer unique insight into the clinical factors which promote NK cell homing/persistence in the bone marrow niche after adoptive immunotherapy. Board approved retrospective study, we identified patients who received NK cell  therapy for relapsed/recurrent AML between 2003 and 2014  including patients treated under seven prospective clinical  trials (MT2003-1, MT2003-23, MT2004-25, MT2008-36,  MT2010 -02, MT2010-10, and MT2011-05). The patients enrolled in the NK cell immunotherapy studies had relapsed or primary refractory AML or other high-grade myeloid neoplasm with adequate organ function, who had failed ≥ 2 prior therapies. The patients had active disease based on hematopathology assessment of bone marrow biopsy findings. All patients received lymphodepleting chemotherapy with fludarabine and cyclophosphamide. Patient characteristics including age, percentage of marrow blasts at time of treatment, and the number of prior therapies have been described in more detail previously. 5, 11 There were no restrictions based on karyotype, mutational status, or risk group beyond those stated previously. A subset received TBI and a separate subset received denileukin diftitox, an anti-CD25 antibody coupled with diphtheria toxin aimed to deplete regulatory T cells. For the subset of patients who received TBI, dosing was 400 cGy. For the subset of patients who received denileukin diftitox, dosing varied [1 (n = 11) or 2 doses (n = 4) of IL2DT, 12 (n = 11) or 18 mg/kg (n = 4) IV, at day −1 ± −2]. Details are previously published. 11 The donors were HLA haploidentical family members, who underwent unstimulated mononuclear cell collections by apheresis, with the product enriched for NK cells using large-scale immunomagnetic selection (CliniMACS, Miltenyi Biotech, Bergisch Gladbach, Germany) by depletion of CD3 + T cells, and CD19 + B cells in some protocols. NKcellular products were prepared following good manufacturing practice conditions in the University of Minnesota Molecular and Cellular Therapy Facility, as previously described. 12 The donor NK cells were activated by incubation with IL-2 (or IL-15 in 1 protocol) overnight. Patients received activated donor NK cells by intravenous infusion at 1.5-8×10 7 /kg body weight. Subcutaneous IL-2 (or, in 1 protocol, intravenous IL-15) was given for 6 doses over 2 weeks to facilitate survival/expansion of infused NK cells. The protocol and consent procedures were approved by the University of Minnesota Institutional Review Board (clinicaltrials.gov NCT00274846 and NCT01106950).
METHODS

In this Institutional Review
Clinicopathologic characteristics were extracted from the electronic medical record. Hematoxylin and eosinstained core sections and Wright-Giemsa-stained aspirate and peripheral blood smears were evaluated by study authors (L.M., E.L.C., and B.G.).
CD56 immunohistochemical stain (clone MRQ-42; Cell Marque, Rocklin, CA) was performed on 5-µm thick, acetic zinc formalin-fixed, decalcified, paraffin-embedded core biopsy sections using a Ventana Ultra automated stainer (Tucson, AZ). Flow cytometry was performed on marrow aspirate specimens according to the protocols at the time of biopsy and the data were reanalyzed to enumerate total lymphocytes and NK cells. Relevant antibodies used included: CD3 epsilon, CD56, and CD45 (Becton Dickinson, San Jose, CA). The samples were acquired on FACS-Canto instruments (Becton Dickinson) and analyzed using Kaluza Software (Beckman Coulter, Indianapolis, IN). Lymphocytes were enumerated by standard gating on CD45 versus side scatter plots and NK cells were defined as CD56 + , surface CD3 − lymphocytes. To evaluate disease control/clearance, we obtained the marrow blast percentage from the final pathology report. We used <5% blasts to indicate morphologic remission of leukemia while ≥ 5% blasts were considered residual/persistent disease. Cases with no blast percentage reported due to very low bone marrow cellularity precluding differential count (n = 13) were retrospectively reviewed by the study authors to determine disease status.
As a reference cohort, we identified 56 patients with an underlying diagnosis of AML with bone marrow biopsies performed at 14-21 days (average, 16 d) after standard induction chemotherapy for AML (cytarabine and daunorubicin 7+3). Microscopic evaluation of CD56 staining and review of flow cytometry data were performed in the reference cohort as described for the study cases. Six of the reference cases were excluded from the analysis of CD56 staining due to CD56 positivity on leukemic blasts. We also had flow cytometry data available for analysis of NK cell content in the bone marrow aspirates for 46 of the reference cases.
To test the association between CD56 density on core biopsies or NK cell percentage by flow cytometry and variables of interest, Mann Whitney, Wilcoxon rank-sum, Kruskal-Wallis, and the χ 2 tests were performed, as appropriate. To investigate the relationships between CD56/HPF density, low-power CD56 percentage, and NK cell percentages by flow cytometry, the Spearman correlation coefficients were obtained. Statistical analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC), GraphPad Prism version 6 for Windows (GraphPad Software, LaJolla, CA), and R version 3.4.0 (www.R-project.org/).
RESULTS
We identified 109 patients, 47 females and 62 males, with an average age of 47 years (range, 4-75) at the time of NK cell therapy. All patients had a preinfusion biopsy showing residual/recurrent AML, obtained an average of 20 days before infusion (range, 7-92), with an average cellularity of 54% (range, 5%-100%) and an average blast percentage of 35% (range, 2%-94%) at that time. The routine first postinfusion biopsies obtained an average of 14 days (range, 9-33 d) after adoptive immunotherapy showed a wide range of cellularity with 45 having a cellularity of ≤ 5% and 10 having a cellularity of ≥ 90%. The majority of cases showed leukopenia (104/109, 95%) with a white blood cell <4.0 K/µl.
In total, 89 of the first postinfusion biopsies could be evaluated for CD56 + cell density. We did not evaluate the CD56 immunohistochemical stain for 14 specimens due to missing biopsy material, very small and/or nonrepresentative biopsy, poor preservation of the sections, or unacceptable immunohistochemical staining. In addition, we did not quantify CD56
+ cell density for 6 specimens due to evident staining of leukemic cells with CD56, precluding accurate distinction between NK cells and blasts. The CD56 expression by blasts was corroborated by flow cytometry results showing a CD56 + immunophenotype. In total, 54 of the first postinfusion biopsies had a concurrent marrow aspirate specimen which could be evaluated for NK cells by flow cytometry. For the reference cohort of 56 cases obtained following standard induction chemotherapy for AML, 6 cases showed prominent CD56 positivity on leukemic cells and were excluded from the analysis of CD56 staining. Flow cytometry data were available for analysis of NK cell content in the bone marrow aspirates for 46 of the reference cases.
Characteristics of the study and reference cases are presented in Table 1 . The distribution of NK cell density (expressed as average number of CD56 + cells per microscopic, CD56/HPF) and percentage of NK cells in the lymphocyte population by flow cytometry in the study and reference groups are shown in Figures 1A and B , respectively. The distribution of CD56/HPF density differed between the study group and reference group (P = 0.001) with the median
CD56
+ cell density higher in the reference group (median, 8.2 vs. 3.4). Despite the higher median CD56 + cell density in the reference group, 30% (27/89) of the study patients with first postinfusion biopsies evaluable for CD56 by immunohistochemistry had a CD56 + cell density above the median CD56 + cell density of the reference cases. CD56 + NK cells were either evenly distributed or present in focal clusters (Figs. 2A, B) . They were present in both areas of active hematopoiesis and in hypocellular areas (Figs. 2C, D) . Frequently the NK cells were seen in the sinusoids, apparently attached to the endothelial wall and rare mitoses of CD56 + cells within marrow parenchyma were seen (Fig. 2E) . We did not observe an association of NK cells with large lymphoid aggregates. In total, 31 of the study patients (57%) had an NK cell percentage relative to total lymphocytes by flow cytometry above the median NK cell percentage of reference cases and 23 (43%) had an NK cell percentage by flow cytometry below (Fig. 1B) . (Figs. 3A, 
B). Patients with a CD56
+ cell density by immunohistochemistry above reference cases showed a higher odds of achieving morphologic remission compared with patients without an increase in CD56 + cell density relative to reference cases (P = 0.01, Fig. 3C ). Patients with NK cells representing a greater proportion of lymphocytes above median of reference cases, as demonstrated by flow cytometry, showed more frequent morphologic remission (P = 0.01, Fig. 3D ).
Anti-CD25 and TBI Increase CD56/HPF NK Cell Density in the Bone Marrow NK cell immunotherapy protocols at the University of Minnesota were revised over the years and our study cohort reflects 7 clinical trials; therefore, we investigated the possibility that the CD56/HPF NK cell density in first postinfusion biopsy specimens varied based on lymphodepleting strategy.
One clinical protocol (MT2008-36) was excluded from this particular analysis due to low number of participants (only 1 data point available for this analysis). As can be seen in Figure 4 , there was significant variability between the median CD56/HPF count among the clinical protocols (P = 0.04, Kruskal-Wallis test).
Visual inspection of Figure 4 suggests that the use of denileukin diftitox or the use of TBI may lead to a higher CD56/HPF NK cell density. Therefore, we investigated whether the use of denileukin diftitox affected CD56/HPF NK cell density. As no patient received both denileukin diftitox and TBI, we were able to analyze them independently. Excluding patients who received TBI, there was a higher CD56/HPF NK cell density in the cohort receiving denileukin diftitox compared with those who did not receive denileukin diftitox (P = 0.02, Fig. 5A) . Similarly, excluding patients who received denileukin diftitox, patients who received TBI had a higher CD56/HPF NK cell density compared with patients who did not receive TBI (P = 0.01, Fig. 5B ). We did not see a difference in CD56/ HPF NK cell density depending on the use of IL-2 or IL-15 within our cohort (data not shown).
CD56/HPF NK Cell Density in Tissue Sections has Weak Correlation With the Percentage of NK Cells by Flow Cytometric Evaluation
There was an excellent correlation between the CD56/ HPF count and the low-power CD56 + NK cell percentage, 
DISCUSSION
Adoptive immunotherapy with NK cells has the potential to give some patients with chemotherapy-refractory AML a chance for achieving remission. The use of immunotherapy as a bridge to allogeneic transplantation has gained wide attention worldwide. 13 Factors influencing the effectiveness of NK cell immunotherapy in various clinical settings include the alloreactive potential of NK cells determined by sets of killer immunoglobulin-like receptors (KIR) and HLA genes, the number of alloreactive NK cells infused, 14, 15 the functional status of the NK cells 16, 17 and composition of lymphodepleting + NK cell density within bone marrow core biopsies, comparing patients with persistent disease ( ≥ 5% marrow blasts) and in morphologic remission (< 5% marrow blasts). B, Box-and-whisker plots showing the distribution of the NK cell percentage relative to lymphocytes as determined by flow cytometry performed on marrow aspirate sample, comparing patients with persistent disease and in morphologic remission. C, Bar charts illustrating the number of patients with CD56 + cell density above and below the median value of 8.2 from reference cohort and comparing patients with persistent disease and in morphologic remission. D, Bar charts illustrating the number of patients with NK cell percentage relative to lymphocytes as determined by flow cytometry above and below the median value of 5.5% from reference cohort and comparing patients with persistent disease and in morphologic remission. HPF indicates high power field; NK, natural killer. chemotherapy. 5, 18 In this large cohort of patients treated with allogeneic NK cell immunotherapy we focused on the histopathologic determination of NK cell density in the bone marrow.
We used CD56 immunohistochemical staining as a marker of NK cells within the bone marrow niche. CD56 is one of the forms of neural cell adhesion molecule and is well established as a marker of human NK cells. 18 CD56 expression is not unique to NK cells and can be expressed by other hematopoietic cells including monocytes, plasma cells, and leukemic blasts, and can be acquired by activated T cells. Also rare nonhematopoietic cells of neural or neuroendocrine origin can be positive for CD56. 19 A small number of cases with involvement by numerous CD56 + blasts were excluded from this analysis.
We are not aware of previous studies characterizing the density of NK cells in human bone marrow. Characteristics which may conceivably affect bone marrow density of NK cells include underlying diagnosis, the timing and type of prior chemotherapy, overall marrow cellularity, patient age, sex, other comorbidities, infections, and other factors. An optimal control group for the NK cell immunotherapy patients would be composed of individuals of similar age with refractory AML who had received lymphodepleting chemotherapy conditioning regimen 14 days prior (fludarabine-cytoxan or similar), but did not receive allogeneic NK cell infusion. Such control group is not available to us. In the current study the median density of NK cells in reference cohort of AML postinduction biopsies is higher than median density in NK cell immunotherapy patients. Although the reason for this finding is not clear, we speculate that lymphodepleting conditioning chemotherapy used in the NK cell immunotherapy patients (fludarabine, cytoxan) more effectively depletes lymphocytes including NK cells, compared with daunorubicine and cytarabine (7+3 induction). Moreover, the study group included heavily pretreated patients with overall low bone marrow cellularity, whereas the reference AML cohort for the most part showed early hematopoietic recovery.
On the basis of our findings, we hypothesize that CD56 immunohistochemical staining of bone marrow core biopsy specimens is a more accurate representation of the bone marrow NK cell population than flow cytometry of marrow aspirate specimens, due to the likely hemodilution of marrow aspirate specimens. Hemodilution is known to be a factor in bone marrow aspirate specimens particularly in cases with low marrow cellularity and fibrosis. We show that NK cell immunotherapy patients who achieved higher NK cell density and higher percentage NK cells by flow cytometry compared with AML reference cohort had better control of disease.
Studies on animal models have previously shown that NK cell populations can expand in allogeneic hosts 20 and have the ability to home to lymphoid tissues. As well, in a model of NK cell response to viral infection the primary site of NK cell proliferation was shown to be in the bone marrow, 10 even when the bone marrow was not the primary target of the virus. 8 Bone marrow is the primary site of AML involvement and it is conceivable that the homing and persistence of NK cells in the bone marrow could determine to some extent whether or not leukemia can be eradicated. The rules governing trafficking of human NK cells after therapeutic infusion are not well studied and our work describes a unique set of findings. We show that NK cells can persist and expand in the bone marrow within a month postinfusion and that an increase in CD56 + NK cell density in the bone marrow at this timepoint correlates with leukemia clearance.
By comparing NK cell density between various clinical protocols, we identified 2 clinical treatment factors which were associated with higher NK cell density: the use of TBI and the use of denileukin diftitox, a therapeutic antibody against CD25 coupled with toxin. We hypothesize that the action of CD25-targeting immunotoxin depends on targeting T regulatory cells, a subset of T cells with distinctly higher expression of CD25 and immunosuppressive properties. 11 T regulatory cells have been shown to dampen NK cell response 21 and their elimination could result in improved NK cell activity. The mechanism of TBI is less clear; it has been previously proposed that it augments lymphodepletion and improves availability of IL-15. 5 More recently irradiation has been shown to increase NK cell trafficking to sarcoma in an animal model, corroborating our observation. 22 The additive effect of radiation and immunotherapy can be also explained by upregulation of tumor antigens including NKG2D ligands, as well as chemokines and adhesion molecules increasing recruitment of effector cells.
In summary, our study suggests that increased NK cell homing/persistence in the bone marrow 2-3 weeks after adoptive NK cell immunotherapy was associated with higher likelihood of achieving leukemia remission and appeared to be promoted by TBI and denileukin diftitox. These original findings may be helpful in guiding future immunotherapy with NK cells.
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